Cancer care startup Thyme Care raises $125 million in a Series E funding round, increasing its valuation to more than $2 billion. The company says the funding supports its efforts to address gaps in disease treatment and accelerate growth.
Multiple outlets describe the round as including major health investors, citing participation from Morgan Health, CVS Health Ventures, and Humana, along with other strategic payers and providers. PR Newswire adds that Thyme Care establishes a new corporate structure, forming “Thyme Companies” as a parent entity intended to broaden the company’s reach across the oncology ecosystem. CNBC focuses on the funding amount and the resulting valuation increase, while PR Newswire emphasizes both the investor roster and the new organizational setup.
Across coverage, the key shared points are the $125 million scale of the Series E, the valuation exceeding $2 billion, and the company’s stated goal of expanding impact in oncology. Details on the precise terms beyond valuation and the full list of participating investors are not fully aligned across the provided summaries.
